🔗 Share this article

A shadow economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Followers are encouraged to contact these profiles privately for source information, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Additionally, a flourishing trade exists on Telegram, where groups with thousands of participants share comparison images, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before redirecting buyers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.

Medical Experts Voice Worries

However, physicians and chemists have warned that the distribution of what is still an unlicensed medication in the UK is worrisome and could result in users injecting products of unknown origin.

Some experts said the popularity for the experimental drug could be connected to the increasing cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Selling retatrutide on TikTok or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for human use under the British medical regulations.

Several influencers try to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still breach medicines, marketing, and customer regulations, risking penalties, prosecution or imprisonment.

Platform Reaction and Content Elimination

Based on the social media company, the service has removed problematic content and prohibited related hashtags and search suggestions. The organization said it was committed to maintaining the platform secure and allocating resources in strengthening compliance measures.

Digital Marketplace Operations

Research also discovered communities with up to nine thousand participants selling retatrutide using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly brings up groups with numerous of users, filled with photos of weight loss, positive reviews and step-by-step instructions for preparing or injecting at residence.

After moments of entering one community, a vendor shared WhatsApp details, where most purchases occur. The vendor provided an instruction manual and promised delivery within two days. When questioned whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about weight, medical conditions or past usage.

Product Details and Pricing

Within these communities, messages show black plastic parcels with postal service labels, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at residence with purified liquid, or ready-to-use injectors usually priced at 160 pounds for 20mg. When asked how much time a injector should be used, vendors give conflicting answers varying between a several days to “depends on your body”.

Platform Moderation and Safety Actions

A representative for the messaging service said it regularly monitored dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they cannot confirm. Although the science behind this drug is valid, these digital products may not contain what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor connected the surge in interest to current cost increases for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit injections are highly risky. You cannot know what’s contained or whether the conditions they were produced in was sterile,” she explained.

Her team has already seen patients harmed by self-injection from unverified sources. “We recognize the frustration, but purchasing from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A representative from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to possibly serious health risks”.